PURPOSE: Tumors encounter endoplasmic reticulum stress during tumor growth and activate an adaptive pathway known as the unfolded protein response (UPR). Because this pathway is induced by the tumor microenvironment, it is a promising target for cancer therapy. We have previously demonstrated that X-box binding protein 1 (XBP-1), a key regulator of the UPR, was required for survival under hypoxia and critical for tumor growth in tumor xenografts. In this study, we investigated the role of XBP-1 in regulating tumor angiogenesis. METHODS: We used an intradermal angiogenesis model to quantify the effect of XBP-1 on angiogenesis. We also used a human tumor xenograft model to assay for tumor growth delay. We determined vascular endothelial growth factor (VEGF) expression by quantitative polymerase chain reaction and ELISA. Finally, we stained human pancreatic adenocarcinoma specimens for XBP-1 expression and correlated the expression pattern of XBP-1 with CD31 (endothelial cell marker) expression. RESULTS: We demonstrated that XBP-1 is essential for angiogenesis during early tumor growth. Inhibiting XBP-1 expression by short-hairpin RNA sequence specific for XBP-1 reduced blood vessel formation in tumors from mouse embryonic fibroblast cells and human fibrosarcoma tumor cells (HT1080). Expressing a dominant-negative form of IRE1alpha also reduced blood vessel formation in tumors. Moreover, expression of spliced XBP-1 (XBP-1s) restored angiogenesis in IRE1alpha dominant-negative expressing cells. We further demonstrated that XBP-1-mediated angiogenesis does not depend on VEGF. CONCLUSIONS: We propose that the IRE1alpha-XBP-1 branch of the UPR modulates a complex proangiogenic, VEGF-independent response that depends on signals received from the tumor microenvironment.
PURPOSE:Tumors encounter endoplasmic reticulum stress during tumor growth and activate an adaptive pathway known as the unfolded protein response (UPR). Because this pathway is induced by the tumor microenvironment, it is a promising target for cancer therapy. We have previously demonstrated that X-box binding protein 1 (XBP-1), a key regulator of the UPR, was required for survival under hypoxia and critical for tumor growth in tumor xenografts. In this study, we investigated the role of XBP-1 in regulating tumor angiogenesis. METHODS: We used an intradermal angiogenesis model to quantify the effect of XBP-1 on angiogenesis. We also used a humantumor xenograft model to assay for tumor growth delay. We determined vascular endothelial growth factor (VEGF) expression by quantitative polymerase chain reaction and ELISA. Finally, we stained humanpancreatic adenocarcinoma specimens for XBP-1 expression and correlated the expression pattern of XBP-1 with CD31 (endothelial cell marker) expression. RESULTS: We demonstrated that XBP-1 is essential for angiogenesis during early tumor growth. Inhibiting XBP-1 expression by short-hairpin RNA sequence specific for XBP-1 reduced blood vessel formation in tumors from mouse embryonic fibroblast cells and humanfibrosarcoma tumor cells (HT1080). Expressing a dominant-negative form of IRE1alpha also reduced blood vessel formation in tumors. Moreover, expression of spliced XBP-1 (XBP-1s) restored angiogenesis in IRE1alpha dominant-negative expressing cells. We further demonstrated that XBP-1-mediated angiogenesis does not depend on VEGF. CONCLUSIONS: We propose that the IRE1alpha-XBP-1 branch of the UPR modulates a complex proangiogenic, VEGF-independent response that depends on signals received from the tumor microenvironment.
Authors: Jaime D Blais; Christina L Addison; Robert Edge; Theresa Falls; Huijun Zhao; Kishore Wary; Costas Koumenis; Heather P Harding; David Ron; Martin Holcik; John C Bell Journal: Mol Cell Biol Date: 2006-10-09 Impact factor: 4.272
Authors: A C Koong; V K Mehta; Q T Le; G A Fisher; D J Terris; J M Brown; A J Bastidas; M Vierra Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: Yijun Chen; Douglas E Feldman; Changchun Deng; James A Brown; Anthony F De Giacomo; Allison F Gaw; Gongyi Shi; Quynh T Le; J Martin Brown; Albert C Koong Journal: Mol Cancer Res Date: 2005-12 Impact factor: 5.852
Authors: Benjamin Drogat; Patrick Auguste; Duc Thang Nguyen; Marion Bouchecareilh; Raphael Pineau; Josephine Nalbantoglu; Randal J Kaufman; Eric Chevet; Andréas Bikfalvi; Michel Moenner Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701
Authors: Yi Yang; Bai-Jun Cheng; Hong Jian; Zhi-Wei Chen; Yi Zhao; Yong-Feng Yu; Zi-Ming Li; Mei-Lin Liao; Shun Lu Journal: Am J Transl Res Date: 2017-02-15 Impact factor: 4.060
Authors: Roberto Bravo; Valentina Parra; Damián Gatica; Andrea E Rodriguez; Natalia Torrealba; Felipe Paredes; Zhao V Wang; Antonio Zorzano; Joseph A Hill; Enrique Jaimovich; Andrew F G Quest; Sergio Lavandero Journal: Int Rev Cell Mol Biol Date: 2013 Impact factor: 6.813
Authors: Dadi Jiang; Arvin B Tam; Muthuraman Alagappan; Michael P Hay; Aparna Gupta; Margaret M Kozak; David E Solow-Cordero; Pek Y Lum; Nicholas C Denko; Amato J Giaccia; Quynh-Thu Le; Maho Niwa; Albert C Koong Journal: Mol Cancer Ther Date: 2016-06-15 Impact factor: 6.261
Authors: David A Hess; Sean E Humphrey; Jeff Ishibashi; Barbara Damsz; Ann-Hwee Lee; Laurie H Glimcher; Stephen F Konieczny Journal: Gastroenterology Date: 2011-06-24 Impact factor: 22.682